Lugol's iodine
2% Lugol's iodine solution | |
| Clinical data | |
|---|---|
| Other names | Potassium triiodide, Lugol's solution, aqueous iodine, strong iodine solution[1] |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | topical, by mouth |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | I3K |
| Molar mass | 419.812 |
Lugol's iodine, also known as aqueous iodine and strong iodine solution, is a solution of potassium iodide with iodine in water.[2] It is a medication and disinfectant used for a number of purposes.[3][4] Taken by mouth it is used to treat thyrotoxicosis until surgery can be carried out, protect the thyroid gland from radioactive iodine, and to treat iodine deficiency.[4][5] When applied to the cervix it is used to help in screening for cervical cancer.[6] As a disinfectant it may be applied to small wounds such as a needle stick injury.[3] A small amount may also be used for emergency disinfection of drinking water.[7]
Side effects may include allergic reactions, headache, vomiting, and conjunctivitis.[4][1] Long term use may result in trouble sleeping and depression.[4] It should not typically be used during pregnancy or breastfeeding.[4] Lugol's iodine is a liquid made up of two parts potassium iodide for every one part elemental iodine in water.[8]
Lugol's iodine was first made in 1829 by the French physician Jean Lugol.[7][8] It is on the World Health Organization's List of Essential Medicines.[9][10] Lugol's iodine is available as a generic medication and over the counter.[1] Lugol's solution is available in different strengths of iodine. Large volumes of concentrations more than 2.2% may be subject to regulation.[11]
- ^ a b c "Strong Iodine Solution". The American Society of Health-System Pharmacists. Archived from the original on 13 January 2017. Retrieved 8 January 2017.
- ^ Kaiho T (2014). Iodine Chemistry and Applications. John Wiley & Sons. p. 55. ISBN 9781118466292. Archived from the original on 18 September 2017.
- ^ a b Block SS (2001). Disinfection, Sterilization, and Preservation. Lippincott Williams & Wilkins. p. 177. ISBN 9780683307405. Archived from the original on 13 January 2017.
- ^ a b c d e British National Formulary: BNF 69 (69th ed.). British Medical Association. 2015. p. 493. ISBN 9780857111562.
- ^ Lugol's solution Drug Information, Professional. 1994. Archived from the original on 13 January 2017. Retrieved 11 January 2017.
- ^ Fokom-Domgue J, Combescure C, Fokom-Defo V, Tebeu PM, Vassilakos P, Kengne AP, et al. (July 2015). "Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and meta-analysis of diagnostic test accuracy studies". BMJ. 351: h3084. doi:10.1136/bmj.h3084. PMC 4490835. PMID 26142020.
- ^ a b Preedy VR, Burrow GN, Watson RR (2009). Comprehensive Handbook of Iodine: Nutritional, Biochemical, Pathological and Therapeutic Aspects. Academic Press. p. 135. ISBN 9780080920863. Archived from the original on 12 August 2017.
- ^ a b Sneader W (2005). Drug Discovery: A History. John Wiley & Sons. p. 67. ISBN 9780471899792. Archived from the original on 26 August 2017.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ Cite error: The named reference
fr0702was invoked but never defined (see the help page).